Method for constructing chicory-poria compound fingerprint, and fingerprint and use thereof

MYPI2025004772A0Undetermined Publication Date: 2025-02-11BEIJING UNIV OF CHINESE MEDICINE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004772
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-11
Filing Date
2024-02-02
Publication Date
2025-02-11

AI Technical Summary

Technical Problem

The existing technology lacks effective methods to deeply analyze the impact of differences in the effective ingredients of Juling Compound on the quality of drug products, and it is difficult to comprehensively, objectively and accurately evaluate the quality of Juling Compound.

Method used

Ultra-high performance liquid chromatography (UHPLC) technology is used to construct the fingerprint of Juling compound. By selecting appropriate mobile phase composition, gradient elution program, detection wavelength, column and column temperature, the fingerprint of the fingerprint of Chinese medicine chromatography is similar. The degree evaluation system performs quality control of Juling compound prescription.

Benefits of technology

It has achieved comprehensive, objective and accurate detection and evaluation of the quality of Juling compound, ensured the safety and effectiveness of the drug, and provided a scientific basis for the quality control of Juling compound.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025004772_DRAWING_001
    Figure PI2025004772_DRAWING_001
  • Figure PI2025004772_DRAWING_002
    Figure PI2025004772_DRAWING_002
Patent Text Reader

Abstract

The present disclosure discloses a method for constructing a fingerprint chromatogram of a Ju-Ling herbal compound, including: (1) preparing the Ju-Ling herbal compound into a test solution; (2) preparing a mixed reference substance solution using chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, swertiamarin, gentiopicroside, sweroside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercitrin, kaempferol-3-O-rutinoside, and narcissin; and (3) separately injecting the test solution and the mixed reference substance solution into a high-performance liquid chromatograph, and performing similarity analysis on chromatograms obtained to obtain the fingerprint chromatogram of the Ju-Ling herbal compound. The present disclosure also provides the fingerprint chromatogram of the Ju-Ling herbal compound obtained by the method and its use in identifying and / or evaluating the quality of the Ju-Ling herbal compound. The fingerprint chromatogram of the Ju-Ling herbal compound according to the present disclosure could comprehensively, objectively, and accurately test and evaluate the quality of the Ju-Ling herbal compound, thereby ensuring the safety and efficacy of medication for patients.
Need to check novelty before this filing date? Find Prior Art

Description

Construction method of fingerprint of Juling compound prescription and its fingerprint and application

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to a Chinese patent application filed with the Patent Office of China on August 11, 2023, with application number 202311014248.9 and entitled “Method for constructing fingerprint spectrum of Juling compound prescription and its fingerprint spectrum and application”, the entire contents of which are incorporated by reference into this disclosure. Technical Field

[0003] The present disclosure relates to the technical field of traditional Chinese medicine detection, and in particular to a method for constructing a fingerprint spectrum of Juling compound prescription, as well as its fingerprint spectrum and application. Background Art

[0004] The Juling Compound Recipe is a highly condensed summary of the experience of Professor Zhang Bing, a renowned traditional Chinese medicine practitioner, in treating arthralgia and acute and chronic gouty arthritis. It embodies his integrative approach to treating metabolic diseases. Professor Zhang Bing believes that while gout may manifest in the joints, its underlying cause is a disordered uric acid metabolism, induced by external factors. Therefore, treatment should focus on strengthening the spleen and removing dampness, regulating uric acid metabolism, and resolving turbidity, eliminating arthralgia, and preventing urate accumulation. The Juling Compound Recipe consists of chicory, wild smilax, Chinese gentian, Poria cocos, and Sophora japonica. Chicory and wild smilax serve as the main ingredients to strengthen the spleen, remove dampness, and resolve turbidity, promote joint circulation, and regulate uric acid metabolism. Poria cocos and Chinese gentian serve as the auxiliary ingredients, dispelling rheumatism, eliminating pain, and addressing the swelling and pain associated with gouty inflammation. Sophora japonica serves as the adjuvant ingredient, clearing heat, cooling blood, and relieving inflammation and pain. The entire recipe works together to strengthen the spleen, remove dampness, resolve turbidity, reduce acid, reduce swelling, and relieve pain. Bibliographic and network pharmacology studies have shown that this prescription contains a variety of chemical components that can act on the production, excretion and inflammatory pathways of uric acid, and has the advantages of multi-component, multi-target and multi-functional prevention and treatment. It is a comprehensive anti-gout drug that is consistent with the modern pathological understanding of gout.

[0005] At present, the research on Juling compound focuses on clinical application and pharmacology and efficacy, but there is a lack of effective methods to deeply analyze the impact of differences in intrinsic active ingredients on the quality of Juling compound.

[0006] Fingerprints of traditional Chinese medicines are an effective means of identifying traditional Chinese medicine products and evaluating their quality. For example, "Study on the Construction and Pattern Recognition of HPLC Fingerprints of Chicory and Hairy Chicory" (China Journal of Traditional Chinese Medicine, Vol. 38, No. 9, pp. 1401-1405) studied the construction method of HPLC fingerprints of chicory and hairy chicory and the application of the obtained HPLC fingerprints. However, the ingredients of traditional Chinese medicine compound prescriptions are complex, and the fingerprint construction method used for single Chinese medicinal materials in this document is not applicable to traditional Chinese medicine compound prescriptions. In addition, the document uses the organic solvent methanol for ultrasonic extraction of chicory and hairy chicory, which is inconsistent with clinical practice.

[0007] Therefore, it is an urgent problem to establish the ultra-high performance liquid chromatography fingerprint characteristic spectrum of Juling compound, analyze it through the traditional Chinese medicine chromatographic characteristic spectrum similarity evaluation system, and establish a control fingerprint spectrum to provide a basis for the quality control of Juling compound.

[0008] Summary of the Invention

[0009] The purpose of the invention disclosed herein is to provide a method for constructing a fingerprint spectrum of Juling compound prescription and its fingerprint spectrum and application, so as to achieve a comprehensive, objective and accurate evaluation of the quality of Juling compound prescription.

[0010] The present disclosure provides a method for constructing a fingerprint spectrum of Juling compound prescription, comprising the following steps:

[0011] (1) Prepare the Juling compound into a test solution;

[0012] (2) preparing a mixed reference solution using at least two reference substances selected from the group consisting of chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutoside, gentiopicroside, scutoside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside, and narcissin;

[0013] (3) The test solution and the mixed reference solution are respectively injected into a high performance liquid chromatograph, and the obtained chromatograms are subjected to similarity analysis to obtain the fingerprint of the Juling compound.

[0014] Optionally, in step (1), the extract powder or extract powder of the Juling compound is extracted with methanol, and the obtained supernatant is filtered to obtain a filtrate as the test solution;

[0015] Preferably, in step (1), the extract powder or extract powder of the Juling compound is extracted with 70% methanol, and the obtained supernatant is filtered with a 0.22 μm microporous filter membrane to obtain a filtrate as the test solution.

[0016] Optionally, in step (2), a mixed reference solution is prepared using chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutoside, gentiopicroside, scutoside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside and narcissin.

[0017] Optionally, in step (2), each reference substance is mixed and then dissolved in methanol to obtain the mixed reference substance solution; or, each reference substance is separately prepared into a reference substance solution using methanol, and then mixed to obtain the mixed reference substance solution;

[0018] Preferably, in step (2), each reference substance is mixed in equal proportions and then dissolved in 70% methanol to obtain the mixed reference substance solution in which the content of each reference substance is 1 μg / ml; or, each reference substance is separately prepared into a 100 μg / ml reference substance solution using 70% methanol, and then mixed to obtain the mixed reference substance solution in which the content of each reference substance is 1 μg / ml.

[0019] Optionally, in step (3), the chromatographic column of the high performance liquid chromatograph is an ACCQUITY UPLC HSS T3 chromatographic column, with methanol as mobile phase A, 0.1% formic acid aqueous solution as mobile phase B, a flow rate of 0.3 mL / min, a column temperature of 30° C., an injection volume of 2 μL, and a detection wavelength of 300 nm;

[0020] Preferably, the chromatographic column of the high performance liquid chromatograph adopts an ACCQUITY UPLC HSS T3 chromatographic column with a specification of 2.1×100 mm and 1.8 μm.

[0021] Optionally, in step (3), the elution conditions of the high performance liquid chromatography are:

[0022] From 0 to 2 minutes, the volume fraction of mobile phase A increased from 5% to 10%, and the volume fraction of mobile phase B decreased from 95% to 90%;

[0023] From 2 to 16 minutes, the volume fraction of mobile phase A increased from 10% to 40%, and the volume fraction of mobile phase B decreased from 90% to 60%;

[0024] From 16 to 26 minutes, the volume fraction of mobile phase A increased from 40% to 54%, and the volume fraction of mobile phase B decreased from 60% to 46%;

[0025] From 26 to 26.5 minutes, the volume fraction of mobile phase A increased from 54% to 95%, and the volume fraction of mobile phase B decreased from 46% to 5%;

[0026] 26.5-27.5 minutes, the volume fraction of mobile phase A is 95%, and the volume fraction of mobile phase B is 5%;

[0027] From 27.5 to 28 minutes, the volume fraction of mobile phase A decreased from 95% to 5%, and the volume fraction of mobile phase B increased from 5% to 95%.

[0028] The present disclosure also provides a fingerprint spectrum of Juling compound obtained by the above-mentioned construction method, wherein the fingerprint spectrum of Juling compound includes 15 fingerprint peaks. Among them, the relative retention time of peak 2 is 9.64 min, and the corresponding chemical substance is chlorogenic acid; the relative retention time of peak 3 is 10.57 min, and the corresponding chemical substance is 6'-O-β-D-glucosylgentiopicroside; the relative retention time of peak 5 is 11.51 min, and the corresponding chemical substance is gentiopicroside; the relative retention time of peak 8 is 16.73 min, and the corresponding chemical substance is neoastilbin; the relative retention time of peak 9 is 17.16 min, and the corresponding chemical substance is astilbin; the relative retention time of peak 10 is 18.50 min, and the corresponding chemical substance is rutin; the relative retention time of peak 11 is 18.90 min, and the corresponding chemical substance is isoastilbin.

[0029] The present disclosure also provides an application of the above-mentioned Juling compound fingerprint in identifying and / or evaluating the quality of Juling compound.

[0030] The present disclosure also provides a method for identifying and / or evaluating the quality of Juling Compound, comprising: comparing the high performance liquid chromatogram of the Juling Compound to be tested with the above-mentioned Juling Compound fingerprint, and identifying those with a similarity greater than 0.9 as qualified.

[0031] It can be seen from the above technical solutions that the method for constructing the fingerprint spectrum of Juling compound prescription disclosed herein and its fingerprint spectrum and application have at least the following beneficial effects:

[0032] Based on the structural properties of the active ingredients contained in the Juling Compound, including flavonoids, organic acids, and iridoid glycosides, this disclosure experimentally determined chromatographic analysis conditions, including mobile phase composition, gradient elution procedure, detection wavelength, chromatographic column, and column temperature. Multiple experimental verifications have demonstrated that the Juling Compound fingerprint obtained using the disclosed construction method can comprehensively, objectively, and accurately detect and evaluate the quality of the Juling Compound, which is of great significance for ensuring the safety and effectiveness of patient medication.

[0033] This disclosure uses ultra-high performance liquid chromatography (UHPLC) to more comprehensively reveal the fingerprint of the complex Juling compound, further complementing the fingerprint studies of the single herbs chicory and chicory. Furthermore, this disclosure uses a water decoction method to extract the Juling compound, which is closer to clinical use.

[0034] Summary of the Figures

[0035] FIG1 shows the retention time of the common fingerprint peaks of 10 batches of Juling compound in Example 1 of the present disclosure.

[0036] FIG2 shows the control fingerprints obtained using 10 batches of Juling compound prescription in Example 1 of the present disclosure.

[0037] Preferred embodiments of the present disclosure

[0038] In order to fully understand the purpose, features and effects of the present disclosure, the present disclosure is described in detail through the following specific embodiments. Except for the following, the methods of the present disclosure adopt conventional methods or devices in the art. Unless otherwise specified, the technical and scientific terms involved in the present disclosure have the meanings commonly understood by those skilled in the art.

[0039] In the present disclosure, the so-called "Juling compound" refers to a traditional Chinese medicine composition made with chicory, Poria, Smilax glabra, Sophora japonica and Gentiana macrophylla as raw materials. Preferably, the traditional Chinese medicine composition is made from the following raw materials: 6 to 18 parts by weight of chicory, 5 to 15 parts by weight of Poria, 10 to 60 parts by weight of Smilax glabra, 5 to 10 parts by weight of Sophora japonica and 3 to 10 parts by weight of Gentiana macrophylla; further preferably, the traditional Chinese medicine composition is made from the following raw materials: 6 to 10 parts by weight of chicory, 10 to 15 parts by weight of Poria, 20 to 40 parts by weight of Smilax glabra, 5 to 10 parts by weight of Sophora japonica and 3 to 10 parts by weight of Gentiana macrophylla; most preferably, the traditional Chinese medicine composition is made from the following raw materials: 9 parts by weight of chicory, 10 parts by weight of Poria, 30 parts by weight of Smilax glabra, 6 parts by weight of Sophora japonica and 9 parts by weight of Gentiana macrophylla. Specifically, reference may be made to the traditional Chinese medicine composition described in the Chinese invention patent application with application number 202210821181.9, which is incorporated into the present disclosure in its entirety by reference.

[0040] Juling compound contains multiple chemical components that act on uric acid production, excretion, and inflammatory pathways, offering the advantages of multiple components, multiple targets, and multiple efficacy. However, current Chinese herbal compound preparations typically rely on only one or two key ingredients for content control, resulting in a single quality control approach and limited indicators. Therefore, existing evaluation methods are unable to fully reflect the quality of Juling compound, which has multiple ingredients, multiple targets, and multiple medicinal properties.

[0041] In response to these problems, the inventors of the present invention applied the traditional Chinese medicine HPLC fingerprint technology to the quality evaluation of Juling Compound. Based on the active ingredients and structural properties of Juling Compound itself, the chromatographic analysis conditions such as the mobile phase composition, gradient elution procedure, detection wavelength, chromatographic column, column temperature, etc. of the HPLC fingerprint technology were optimized and improved, and matching reference substances were screened, thereby proposing a method for constructing the fingerprint of Juling Compound.

[0042] This study used ultra-high performance liquid chromatography (UPLC) instead of traditional HPLC to study the fingerprint of Juling compound, which enabled all active ingredients in the compound to be well separated and detected simultaneously, with more and more stable peaks.

[0043] In a first aspect, the present disclosure provides a method for constructing a fingerprint of a Juling compound prescription, comprising: (1) preparing a test solution of the Juling compound prescription; (2) preparing a mixed reference solution; and (3) injecting the test solution and the mixed reference solution into a high performance liquid chromatograph, performing a similarity analysis on the obtained chromatograms, and obtaining a fingerprint of the Juling compound prescription. The method for constructing a fingerprint of the Juling compound prescription disclosed herein is described in detail below in conjunction with a specific embodiment.

[0044] (1) Prepare the Juling compound into a test solution.

[0045] In the present disclosure, the extract powder or extract powder of Juling Compound can be used to prepare the test solution.

[0046] In a preferred embodiment, a test solution is prepared using a powdered extract of the Juling compound. Specifically, the powdered extract of the Juling compound is accurately weighed and placed in a stoppered conical flask. Extraction is performed with 70% methanol. The extract is cooled to room temperature and weighed again. The missing weight is supplemented with 70% methanol solution. The supernatant is filtered through a filter membrane, and the filtrate is obtained to obtain the Juling compound test solution. The preparation method of the Juling compound extract powder can refer to relevant methods in the prior art and is not specifically limited in this disclosure.

[0047] In another preferred embodiment, the extract powder of Juling Compound is used to prepare the test solution. Specifically, the extract powder is accurately weighed and placed in a stoppered conical flask. 70% methanol (v / v) is added to a constant volume of 10 mL, diluted to 6 mg / mL, shaken, and filtered through ultrasonication for 30 minutes. The filtrate is then filtered through a 0.22 μm microporous membrane to obtain the test solution.

[0048] Among them, the preparation method of the extract powder of the Juling compound can refer to the relevant scheme in the prior art. As an example only, the extract powder of the Juling compound can be prepared by the following method: according to the ratio of the Juling compound, accurately weigh the chicory, qinjiao, sophora japonica, tuckahoe, and smilax glabra slices, add 12 times the amount of water and soak for 30 minutes, and heat and decoct. After boiling, decoct for 1.5 hours and filter. Repeat the extraction 3 times, combine the water decoction, and concentrate it on a rotary evaporator under reduced pressure to contain 1g / mL of crude drug to obtain the compound decoction concentrate. The compound concentrate is placed in an 80°C water bath and steamed until it has no fluidity, then placed in a vacuum drying oven for drying. The drying temperature is maintained at 80°C and dried continuously for 7 days. Take it out, put it to room temperature and crush it to obtain the compound extract powder.

[0049] (2) Prepare mixed reference solution.

[0050] According to the characteristics of the active ingredients of the Juling compound, the present disclosure selects at least two substances from the group consisting of chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutellarin, gentiopicroside, scutellarin, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside and narcissusin as reference substances, and preferably, the present disclosure uses chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutellarin, gentiopicroside, scutellarin, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside and narcissusin as reference substances to prepare a mixed reference solution.

[0051] In the present disclosure, each reference substance can be mixed and then dissolved in methanol to obtain a mixed reference substance solution; alternatively, each reference substance can be separately prepared into a reference substance solution using methanol and then mixed to obtain a mixed reference substance solution.

[0052] In a preferred embodiment, chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutoside, gentiopicroside, scutoside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside, and narcissin reference substances are accurately weighed respectively, placed in a volumetric flask, dissolved with 70% methanol, and shaken to volume, and filtered through a microporous filter membrane to obtain a mixed reference solution.

[0053] In another preferred embodiment, appropriate amounts of chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutoside, gentiopicroside, scutoside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside, and narcissin are accurately weighed and dissolved in 70% methanol to prepare solutions containing approximately 100 μg per 1 ml (i.e., 100 μg / ml reference solution). Accurately measure 1 ml of each of the aforementioned reference solutions and place them in the same 100 ml volumetric flask. Add 70% methanol to the mark and shake well to obtain a mixed reference solution containing 1 μg of each reference substance per 1 ml of the mixed reference solution, i.e., the content of each reference substance in the mixed reference solution is 1 μg / ml.

[0054] (3) The test solution and the mixed reference solution were injected into a high performance liquid chromatograph, and the obtained chromatograms were subjected to similarity analysis to obtain the fingerprint of the Juling compound.

[0055] In the present disclosure, the chromatographic conditions used are: the chromatographic column uses an ACCQUITY UPLC HSS T3 chromatographic column, the specifications of which are preferably an inner diameter of 2.1 mm, a column length of 100 mm, and a particle size of 1.8 μm, methanol as mobile phase A, 0.1% formic acid aqueous solution as mobile phase B, a flow rate of 0.3 mL / min, a column temperature of 30°C, an injection volume of 2 μL, and a detection wavelength of 300 nm.

[0056] In the present disclosure, gradient elution was performed according to the following table:

[0057] The chromatogram obtained by high performance liquid chromatography was imported into the Chinese medicine chromatographic fingerprint similarity evaluation system (version 2012.130723) to obtain the fingerprint of Juling compound.

[0058] It should be noted that the various substances involved in the construction method disclosed herein, such as Chinese medicinal materials, reference substances, etc., can be purchased on the market.

[0059] In a second aspect, the present disclosure provides a fingerprint spectrum of Juling compound prescription, comprising 15 fingerprint peaks.

[0060] Referring to the numbers in Figure 2, the key peaks of the fingerprint of the Juling compound disclosed in the present invention include fingerprint peaks 2, 3, 5, 8, 9, 10, and 11. Among them, the relative retention time of peak 2 is 9.64 min, and the corresponding chemical substance is chlorogenic acid; the relative retention time of peak 3 is 10.57 min, and the corresponding chemical substance is 6'-O-β-D-glucosylgentiopicroside; the relative retention time of peak 5 is 11.51 min, and the corresponding chemical substance is gentiopicroside; the relative retention time of peak 8 is 16.73 min, and the corresponding chemical substance is neoastilbin; the relative retention time of peak 9 is 17.16 min, and the corresponding chemical substance is astilbin; the relative retention time of peak 10 is 18.50 min, and the corresponding chemical substance is rutin; the relative retention time of peak 11 is 18.90 min, and the corresponding chemical substance is isoastilbin.

[0061] The fingerprint spectrum of the Juling compound disclosed in the present invention can be used to comprehensively, objectively and accurately detect and evaluate the quality of the Juling compound. Therefore, in the third aspect, the present invention provides a method for identifying and / or evaluating the quality of the Juling compound, comprising: using the above-mentioned chromatographic conditions and gradient elution procedure to obtain a high-performance liquid chromatogram of the Juling compound to be tested, and comparing the high-performance liquid chromatogram with the fingerprint spectrum of the Juling compound disclosed in the present invention. If the similarity is greater than 0.9, the Juling compound to be tested is considered to be qualified. Example

[0062] The present disclosure is further illustrated by way of examples below, but the present disclosure is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.

[0063] Example 1: Establishment and application of the comparative fingerprint of Juling compound

[0064] 1. Instruments, reagents, and medicinal materials

[0065] Waters ACQUITY UPLC H-CLASS ultra-high performance liquid chromatograph, ACCQUITY UPLC HSS T3 chromatographic column; KQ-5200E ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd., power 250 W, frequency 40 kHz), MTW120 electronic balance (Shenzhen Meifu Electronics Co., Ltd.); grinder (Xiaoxiong Electric Co., Ltd.).

[0066] Methanol, formic acid (chromatographic grade, Fisher, USA); distilled water (Watsons Industrial Co., Ltd., Hong Kong); pure water was provided by the laboratory.

[0067] The 5 medicinal materials in Juling compound were collected from all over the country, with 10 batches of each medicinal material. Their origins and batches are shown in Tables 1 and 2.

[0068] Table 1

[0069] Table 2

[0070] 2. Construction of fingerprint of Juling compound prescription

[0071] (1) Preparation of test solution

[0072] According to 9 grams of chicory, 10 grams of Poria cocos, 30 grams of Smilax glabra, 6 grams of Sophora japonica seeds, and 9 grams of Gentiana macrophylla, accurately weigh the pieces of each batch S1 to S10 in Tables 1 and 2 to obtain 10 batches of test samples. For these 10 batches of test samples, perform the following operations respectively:

[0073] Add 12 times the amount of water and soak for 30 minutes, then heat and decoct. After boiling, decoct for 1.5 hours and filter. Repeat the extraction 3 times, combine the decoctions, and concentrate them on a rotary evaporator under reduced pressure to a crude drug content of 1g / mL to obtain the compound decoction concentrate. Place the compound concentrate in an 80℃ water bath and steam until it has no fluidity, then place it in a vacuum drying oven for drying, maintaining the drying temperature at 80℃ for 7 days. Remove it, bring it to room temperature, and then crush it to obtain the compound extract powder.

[0074] Accurately weigh the extract powder, place it in a stoppered conical flask, add 70% methanol to make up to 10 mL, dilute to 6 mg / mL, shake, and filter by ultrasonication for 30 min. Take the filtrate and filter it with a 0.22 μm microporous membrane to obtain the test solution.

[0075] (2) Preparation of mixed reference solution

[0076] Accurately weigh appropriate amounts of chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutoside, gentiopicroside, scutoside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside, and narcissin reference substances, and dissolve them in 70% methanol to prepare solutions containing approximately 100 μg per 1 ml. Accurately measure 1 ml of each of the above reference substance solutions and place them in a 100 ml volumetric flask. Add 70% methanol to the mark and shake well to obtain a mixed reference solution (1 μg of each reference substance per 1 ml).

[0077] (3) Determination of the fingerprint of Juling compound by ultra-high performance liquid chromatography

[0078] The 10 batches of Juling compound test solution prepared in step (1) and the mixed reference solution prepared in step (2) were respectively injected into the high performance liquid chromatograph.

[0079] Chromatographic conditions: An ACCQUITY UPLC HSS T3 column (inner diameter 2.1 mm, column length 100 mm, particle size 1.8 μm) was used, with methanol as mobile phase A and 0.1% formic acid aqueous solution as mobile phase B. The flow rate was 0.3 mL / min, the column temperature was 30°C, the injection volume was 2 μL, the detection wavelength was 300 nm, and gradient elution was performed according to the table below.

[0080] The fingerprints of the 10 batches of Juling compound solution were exported and imported into the Chinese medicine chromatographic fingerprint similarity evaluation system (version 2012.130723): the chromatographic peaks that existed in the chromatograms of the 10 batches of Juling compound and had high contents were selected as common peaks; the median calculation method was used to generate the control fingerprint of Juling compound, and the relative retention time and relative peak area of ​​each common peak were calculated. There were 15 common fingerprint peaks in the control fingerprint (the fingerprint similarity of the 10 batches of test solution was greater than 0.90).

[0081] The retention times of the 15 common fingerprint peaks are shown in FIG1 , and the control fingerprint spectrum obtained in this example is shown in FIG2 .

[0082] Example 2: Methodological Investigation

[0083] 1. Precision experiment

[0084] The same batch of Juling compound powder was accurately aspirated and a test solution was prepared according to the method of step (1) of the above embodiment 1. The injection was repeated 6 times according to the chromatographic conditions of step (3) of the above embodiment 1. The RSD values ​​of the peak areas of the common peaks 1, 2, 3, 5, 6, 7, 8, and 10 were all <4.0%, and the RSD values ​​of the retention times were all <1.0%, which proved that the instrument had good precision.

[0085] 2. Repeatability test

[0086] The same batch of Juling compound powder was precisely aspirated and 6 test solutions were prepared in parallel according to the method of step (1) of the above embodiment 1. The samples were injected 6 times according to the chromatographic conditions of step (3) of the above embodiment 1. The RSD values ​​of the peak areas of the common peaks 1, 2, 3, 5, 6, 7, 8, and 10 were all <3.5%, and the RSD values ​​of the retention times were all <1.0%, which proved that the method had good repeatability.

[0087] 3. Stability test

[0088] The same batch of Juling compound powder was accurately drawn and a test solution was prepared according to the method of step (1) of the above embodiment 1. The sample was injected and analyzed at 0 h, 1 h, 2 h, 5 h, 12 h and 24 h after sample preparation according to the chromatographic conditions of step (3) of the above embodiment 1. The RSD values ​​of the peak areas of the common peaks 1, 2, 3, 5, 6, 7, 8 and 10 were all <3.5%, and the RSD values ​​of the retention times were all <1.0%, indicating that the test solution had good stability within 24 h.

[0089] Through the above research, it can be determined that the present disclosure uses fingerprint technology to establish the UHPLC fingerprint of Juling Compound, which can quickly and intuitively identify the pharmacological substance basis in complex Chinese herbal decoction systems; at the same time, combined with chemical recognition modes such as grey correlation analysis and partial least squares analysis, the quality differences between batches of samples are evaluated, providing a reference for the study of the key quality attributes of Juling Compound, and providing a useful reference for the preparation process, quality control, and product safety and stability evaluation of subsequent related preparations.

[0090] Finally, it should be noted that the above examples are only specific implementation examples of the present disclosure. Of course, those skilled in the art can make changes and modifications to the present disclosure. If these modifications and variations fall within the scope of the claims of the present disclosure and their equivalent technologies, they should be considered to be within the scope of protection of the present disclosure.

Claims

1. A method for constructing a fingerprint spectrum of Juling compound prescription, characterized in that: The steps include: (1) Prepare the Juling compound into a test solution; (2) preparing a mixed reference solution using at least two reference substances selected from the group consisting of chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutellaria glycoside, gentiopicroside, scutellaria glycoside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside and narcissin; (3) Injecting the test solution and the mixed reference solution into a high performance liquid chromatograph respectively, performing similarity analysis on the obtained chromatograms, and obtaining the fingerprint of the Juling compound.

2. The construction method according to claim 1, characterized in that: In step (1), methanol is used to extract the extract powder or extract powder of the Juling compound, and the obtained supernatant is filtered to obtain a filtrate as the test solution; Preferably, in step (1), the extract powder or extract powder of the Juling compound is extracted with 70% methanol, and the obtained supernatant is filtered with a 0.22 μm microporous filter membrane to obtain a filtrate as the test solution.

3. The construction method according to claim 1, characterized in that: In step (2), a mixed reference solution is prepared using chlorogenic acid, 6'-O-β-D-glucosylgentiopicroside, scutellaria glycoside, gentiopicroside, scutellaria glycoside, 3-O-caffeoylshikimic acid, neoastilbin, astilbin, rutin, isoastilbin, isochlorogenic acid C, quercetin, kaempferol-3-O-rutinoside and narcissusside.

4. The construction method according to claim 3, characterized in that: In step (2), each reference substance is mixed and then dissolved in methanol to obtain the mixed reference substance solution; or each reference substance is prepared into a reference substance solution using methanol, and then mixed to obtain the mixed reference substance solution; Preferably, in step (2), each reference substance is mixed in equal proportions and then dissolved in 70% methanol to obtain the mixed reference substance solution in which the content of each reference substance is 1 μg / ml; or, each reference substance is separately prepared into a reference substance solution of 100 μg / ml using 70% methanol, and then mixed to obtain the mixed reference substance solution in which the content of each reference substance is 1 μg / ml.

5. The construction method according to claim 1, characterized in that: In step (3), the chromatographic column of the high performance liquid chromatograph is an ACCQUITY UPLC HSS T3 chromatographic column, with methanol as mobile phase A, 0.1% formic acid aqueous solution as mobile phase B, a flow rate of 0.3 mL / min, a column temperature of 30° C., an injection volume of 2 μL, and a detection wavelength of 300 nm; Preferably, the chromatographic column of the high performance liquid chromatograph adopts an ACCQUITY UPLC HSS T3 chromatographic column with specifications of 2.1×100 mm and 1.8 μm.

6. The construction method according to claim 5, characterized in that: In step (3), the elution conditions of the high performance liquid chromatograph are: From 0 to 2 minutes, the volume fraction of mobile phase A increased from 5% to 10%, and the volume fraction of mobile phase B decreased from 95% to 90%; From 2 to 16 minutes, the volume fraction of mobile phase A increased from 10% to 40%, and the volume fraction of mobile phase B decreased from 90% to 60%; From 16 to 26 minutes, the volume fraction of mobile phase A increased from 40% to 54%, and the volume fraction of mobile phase B decreased from 60% to 46%; From 26 to 26.5 minutes, the volume fraction of mobile phase A increased from 54% to 95%, and the volume fraction of mobile phase B decreased from 46% to 5%; 26.5-27.5 minutes, the volume fraction of mobile phase A is 95%, and the volume fraction of mobile phase B is 5%; From 27.5 to 28 minutes, the volume fraction of mobile phase A decreased from 95% to 5%, and the volume fraction of mobile phase B increased from 5% to 95%.

7. A fingerprint spectrum of Juling compound obtained by the construction method according to any one of claims 1 to 6, characterized in that: The fingerprint spectrum of the Juling compound prescription includes 15 fingerprint peaks.

8. The fingerprint spectrum of Juling compound prescription according to claim 7 is characterized in that: The relative retention time of peak 2 is 9.64min, and the corresponding chemical substance is chlorogenic acid; the relative retention time of peak 3 is 10.57min, and the corresponding chemical substance is 6'-O-β-D-glucosylgentiopicroside; the relative retention time of peak 5 is 11.51min, and the corresponding chemical substance is gentiopicroside; the relative retention time of peak 8 is 16.73min, and the corresponding chemical substance is neoastilbin; the relative retention time of peak 9 is 17.16min, and the corresponding chemical substance is astilbin; the relative retention time of peak 10 is 18.50min, and the corresponding chemical substance is rutin; the relative retention time of peak 11 is 18.90min, and the corresponding chemical substance is isostilbin.

9. Use of the Juling compound fingerprint spectrum as described in claim 7 or 8 in identifying and / or evaluating the quality of Juling compound.

10. A method for identifying and / or evaluating the quality of Juling Compound, characterized in that: include: Compare the HPLC chromatogram of the Juling compound to be tested with the fingerprint of the Juling compound as described in claim 7 or 8, and identify it as qualified if the similarity is greater than 0.9.